Evaluation of a 1 cm Thyroid Nodule
For a 1 cm thyroid nodule discovered on physical examination, you should immediately order: (1) serum TSH measurement, and (2) high-resolution thyroid ultrasound with risk stratification. These two tests form the foundation of your initial workup and will guide all subsequent management decisions 1.
Initial Laboratory Testing
Measure serum TSH first – this is the best initial laboratory test of thyroid function 1. Based on the TSH result:
If TSH is low: Order free T4 (FT4) and free T3 (FT3), then proceed to thyroid scintigraphy to detect functional autonomy. Nodules that are "hot" (functioning) on scintigraphy and lack suspicious ultrasound features do not require FNA 1.
If TSH is elevated: Add thyroid peroxidase antibodies (TPOAbs) and FT4 measurement 1.
If TSH is normal: Proceed directly to ultrasound evaluation without additional thyroid function tests.
Do not routinely measure calcitonin unless medullary thyroid carcinoma is suspected based on FNA results or family history 1.
High-Resolution Ultrasound with Risk Stratification
All patients with a palpable thyroid nodule must undergo ultrasound examination 1. The ultrasound serves two critical purposes:
- Confirms the nodule size and characteristics (physical exam can overestimate or underestimate actual dimensions)
- Risk-stratifies the nodule using standardized classification systems (ACR TI-RADS or similar)
Ultrasound-Based Risk Categories
The ultrasound findings will classify your nodule into risk categories that determine whether FNA is needed 1, 2:
High US risk features (hypoechoic, taller-than-wide, irregular margins, microcalcifications): FNA is indicated at ≥1 cm 1, 2
Intermediate US risk features (mildly suspicious): FNA recommended if nodule is >10 mm without definite benign appearance 1
Low US risk features (spongiform, isoechoic/hyperechoic, predominantly cystic >50%): FNA only if ≥20 mm or progressively enlarging 1
When to Proceed to Fine-Needle Aspiration
For your 1 cm nodule, FNA should be performed under ultrasound guidance if:
- The nodule shows high-risk ultrasound features (as defined above) 1, 2
- The patient has personal or family history of thyroid cancer 1
- The nodule is subcapsular or paratracheal in location 1
- There are suspicious cervical lymph nodes 1
- The patient has coexistent suspicious clinical findings (e.g., dysphonia, rapid growth) 1
Do not perform FNA if the nodule is functioning ("hot") on scintigraphy and lacks suspicious ultrasound features 1.
Additional Imaging: What NOT to Order
Avoid these tests for routine evaluation 1:
- CT or MRI (not indicated unless assessing substernal extension or airway compression)
- PET/CT (insufficient diagnostic accuracy, high cost; reserve for preoperative staging of known malignancy)
- Thyroid scintigraphy in euthyroid patients (only indicated if TSH is low)
Critical Pitfalls to Avoid
Don't skip the ultrasound: Physical examination alone is insufficient. A palpable nodule requires ultrasound confirmation and risk stratification 1.
Don't biopsy based on size alone: A 1 cm nodule with benign ultrasound features (low US risk) does not require FNA 1, 2. Conversely, smaller nodules (5-10 mm) with high-risk features may warrant biopsy in certain clinical contexts 1.
Don't order calcitonin screening routinely: This should only be done when medullary thyroid carcinoma is specifically suspected 1.
Always use ultrasound guidance for FNA: Palpation-guided FNA is obsolete – ultrasound guidance makes the procedure safer, more reliable, and more accurate 1.
Summary Algorithm
- Order TSH → If low, add FT4/FT3 and scintigraphy
- Order high-resolution thyroid ultrasound with risk stratification
- Determine FNA need based on ultrasound risk features and clinical context
- If FNA indicated: Perform under ultrasound guidance, sampling at least 2 sites within the nodule 1
The primary goal is to identify the small percentage of nodules that are malignant while avoiding unnecessary biopsies and overtreatment of benign or indolent lesions 2, 3.